Filling the need for trusted information on national health issues…

Gates Foundation Backing Phase III Clinical Trial Of New TB Drug Regimen

News outlets report on the announcement of a Phase III clinical trial for a drug regimen that has the potential to fight drug-resistant tuberculosis.

The Guardian: New and better treatments for drug-resistant tuberculosis on the horizon
“A new trial of a novel drug combination that could dramatically shorten treatment for tuberculosis, including some of the drug-resistant strains, will start within the year — as long as enough money can be raised…” (Boseley, 4/23).

Reuters: Gates-backed TB drug to enter late-stage testing
“The first experimental drug that fights both conventional and drug-resistant forms of tuberculosis is advancing to late-stage clinical testing, researchers said on Wednesday, raising hope for a new way to stem the growing threat of drug-resistant TB…” (Steenhuysen, 4/23).

Wall Street Journal: Gates Foundation to Fund New Tuberculosis Drug Trial
“The Bill & Melinda Gates Foundation said Wednesday it would help fund a clinical trial of a promising drug regimen that, if effective, would offer a powerful new tool to fight drug-resistant tuberculosis…” (McKay, 4/23).

TB Alliance: New Tuberculosis Drug Regimen Will Move to Landmark Phase III Clinical Trial
“Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multidrug-resistant tuberculosis (TB) to a global Phase III clinical trial…” (4/23).

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/KaiserFamFound

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.